Triamcinolone acetonide hydrofluoroalkane intranasal - Acton Pharmaceuticals

Drug Profile

Triamcinolone acetonide hydrofluoroalkane intranasal - Acton Pharmaceuticals

Alternative Names: Nasacort HFA Nasal Aerosol; Triamcinolone acetonide HFA intranasal - Acton Pharmaceuticals

Latest Information Update: 01 Apr 2015

Price : $50

At a glance

  • Originator Aventis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Apr 2015 Discontinued - Registered for Seasonal allergic rhinitis and Perennial allergic rhinitis in USA (Intranasal)
  • 21 Oct 2013 Acton Pharmaceuticals has been acquired by Meda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top